Back to Breast Cancer

NCT00373113

NCT00373113
Terminated Phase 3 🇦🇺 Australian site

Who may be able to join

"Who might be able to join this trial:

  • You have been diagnosed with a type of breast cancer called breast adenocarcinoma
  • You have already been treated with two specific types of chemotherapy drugs — an anthracycline and a taxane — either together or one after the other, whether that was before surgery, after surgery, or for advanced disease, with no more than one chemotherapy treatment course given for advanced disease

Who may not be able to join:

  • You have received chemotherapy for advanced or metastatic breast cancer that went beyond treatments containing anthracyclines and taxanes, or you have had multiple separate courses of anthracycline or taxane treatments
  • You have previously been treated with a drug called capecitabine (also known by the brand name Xeloda) at any point

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 3
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
1 November 2006
Est. completion
1 October 2009

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇷 Brazil 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇱 Chile 🇨🇴 Colombia 🇫🇷 France 🇩🇪 Germany Hong Kong 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇵🇪 Peru 🇵🇭 Philippines 🇸🇬 Singapore 🇿🇦 South Africa 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan Turkey (Türkiye) 🇬🇧 United Kingdom

6 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov